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Background: The phase 3 RECORD-1 trial (NCT00410124) established the efficacy and safety of everolimus in
patients with metastatic renal cell carcinoma (mRCC) who progress on sunitinib or sorafenib. In RECORD-1, patients
received 10 mg everolimus daily, with dose reduction to 5 mg daily allowed for toxicity. We have developed a
model of tumor growth dynamics utilizing serial measurements of the sum of the longest tumor diameters (SLD)
from individual RECORD-1 patients to define the dose–response relationship of everolimus.
Results: The model predicts that after 1 year of continuous dosing, the change in SLD of target lesions will be
+142.1%± 98.3%, +22.4%± 17.2%, and –15.7%± 11.5% in the average patient treated with placebo, 5 mg
everolimus, and 10 mg everolimus, respectively. This nonlinear, mixed-effects modeling approach can be used to
describe the dynamics of each individual patient, as well as the overall population. This allows evaluation of how an
actual dosing history and individual covariates impact on the observed drug effect, and offers the possibility of
predicting clinical observations as a function of time.
Conclusions: In this pharmacodynamic model of tumor response, everolimus more effectively shrinks target lesions
in mRCC when dosed 10 mg daily versus 5 mg daily, although a 5-mg dose still shows an antitumor effect. These
data support earlier studies that established 10 mg daily as the preferred clinical dose of everolimus, and improve
our understanding of the everolimus dose–response relationship.
Keywords: Efficacy, Kidney, Oncology, Pharmacodynamics, TherapeuticsBackground
Everolimus is an orally active inhibitor of the mamma-
lian target of rapamycin (mTOR) that has been approved
in 65 countries worldwide for the treatment of patients
with metastatic renal cell carcinoma (mRCC) who pro-
gress on or are intolerant of vascular endothelial growth
factor receptor-tyrosine kinase inhibitor (VEGFr-TKI)
therapy [1].
The serine/threonine kinase mTOR is a key regulator of
cell growth and proliferation, metabolism, and angiogenesis* Correspondence: andrew.stein@novartis.com
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reproduction in any medium, provided the or[2]. Abnormal activation of the mTOR signaling path-
way has been implicated in the pathogenesis of RCC
[3-5]. Two principal downstream effectors are respon-
sible for relaying mTOR signaling: the translational re-
pressor protein eukaryotic initiation factor 4E (eIF-4E)
binding protein 1 (4EBP1) and the ribosomal protein
S6 kinase 1 (S6K1) [6]. Phosphorylation of 4EBP1 by
mTOR causes the release eIF-4E, which then acts to
initiate cap-dependent protein translation. Following
activation by mTOR, S6K1 also regulates protein trans-
lation via phosphorylation of ribosomal protein S6.
Results of preclinical and clinical studies have demon-
strated the relationship between inhibition of mTOR
signaling by everolimus and antitumor efficacy [7-10].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in a syngeneic CA20948 pancreatic rat tumor xenograft
model also dramatically inhibited mTOR signaling (as
measured by inhibition of 4E-BP1 phosphorylation and
S6K1 signaling) in tumor, skin, and peripheral blood
mononuclear cells (PBMCs) [10]. These data were used
to develop a direct-link pharmacokinetic/pharmacody-
namic model that described the relationship between in-
hibition of S6K1 and antitumor effects of different
concentrations of everolimus in tumor-bearing rats. Once
corrected for interspecies pharmacokinetic differences,
this model was applied in a phase 1 dose-escalation trial
to describe changes in S6K1 inhibition in tumor and
PBMCs from patients treated with everolimus [11]. The
model predicted that daily doses of everolimus 5 or
10 mg/day would demonstrate a more profound and sus-
tained effect on S6K1 inhibition than weekly doses of 20,
30, 50, or 70 mg. A subsequent phase 1 dose-escalation
study evaluated the pharmacodynamic effects of the above
doses and schedules of everolimus using biomarkers from
both the 4E-BP1 and S6K1 pathways [11]. Inhibition of
mTOR was achieved at all doses and schedules; however,
more profound inhibition of the pathway was seen with
10 mg daily than with 5 mg daily or any weekly dosing
schedule, as this was the only dose that achieved
complete inhibition of both the 4E-BP1 and S6K1 path-
ways. Based on these phase 1 data, a daily dose of 10 mg
of everolimus was used in a subsequent phase 2 study in
patients with mRCC [12], and in the pivotal phase 3
RECORD-1 trial [13,14].
The RECORD-1 trial was an international, rando-
mized, placebo-controlled study that demonstrated the
efficacy and safety of everolimus over placebo in patients
with mRCC who progressed after initial treatment with
VEGFr-TKIs [13,14]. The primary efficacy end point for
the study was progression-free survival (PFS) per central
radiology review, according to RECIST [15]. Median PFS
was more than doubled by everolimus (4.9 months) ver-
sus placebo (1.9 months) (HR, 0.33; 95% CI: 0.25-0.43;
P< 0.001), thus establishing the efficacy of everolimus
in patients with mRCC [13,14]. Everolimus was also
more effective than placebo at reducing tumor size;Table 1 Regimen and pumor assessment in patients enrolled
Patient category
All
With baseline tumor measurement
Crossed over from placebo to everolimus
Received at least one 5-mg dose of everolimus
Received at least one 5-mg dose and a subsequent tumor size assessment
NA, not applicable.47% of everolimus-treated patients showed a decrease
in the sum of the longest tumor diameters (SLD), com-
pared with 10% of patients receiving placebo [14].
Notably, a retrospective analysis of RECORD-1 iden-
tified a best overall tumor burden reduction of 5% as
the threshold for PFS benefit in everolimus-treated
patients [16].
The RECIST criteria divide patients into 4 response cat-
egories: complete response (CR), partial response (PR),
stable disease (SD), and progressive disease (PD), based on
changes in the SLD of target lesions, the unequivocal pro-
gression or disappearance of nontarget lesions, and the
appearance of new metastases. While RECIST provides a
categoric assessment of patient response, the change in an
individual patient’s tumor size over time provides a con-
tinuous assessment of response. As such, monitoring
change in tumor size over time may enable detection of
therapeutic efficacy using a smaller number of patients
than required with RECIST [17]. Pharmacodynamic mod-
els of the change in tumor size over time have been used
recently to quantify the effects of therapy on solid tumors
[18,19]. Such models may provide information about a var-
iety of factors affecting patient response to a drug, including
demographics, stage of disease, or baseline biomarkers, and
are expected to have an enhanced ability to detect the prog-
nostic significance of such factors as compared with ana-
lyses that employ time-to-event data such as PFS [20]. The
use of dynamic tumor models to link change in tumor size
over time to patient response and survival has been pro-
posed as a tool for improving clinical trial design and
decision-making in oncology drug development [20,21].
Herein, we report our development of a model for
tumor growth dynamics to describe the tumor burden re-
duction response to everolimus in the phase 3 RECORD-1
trial in patients with mRCC. This model was used to ex-
plore the effect of two different doses of everolimus (5 mg
and 10 mg daily) on tumor growth. This methodology
complements prior phase 1 analyses of mTOR pathway
inhibition used to guide dose selection, and directly links
the administered dose of everolimus to change in SLD, a
key variable used in the assessment of PFS, the primary
end point for the RECORD-1 study.in the RECORD-1 Phase 3 Trial
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Of the 416 evaluable patients from the RECORD-1 trial,
407 (97.8%) had at least 1 baseline tumor assessment by
the local investigator and were included in this analysis
(Table 1); there were a total of 1569 individual tumor
measurements. Baseline tumor measurements were
obtained for 272/277 patients in the everolimus arm and
135/139 patients in the placebo arm. The majority
(79.9%) of patients on the placebo arm crossed over to
everolimus after disease progression, after a mean pla-
cebo treatment duration of 96.5 days. A total of 98
patients, 69 patients from the everolimus arm and 29
patients from the placebo arm, received at least 1 dose
adjustment of everolimus to 5 mg daily over the course
of the trial. Among these 98 patients, the mean duration
of everolimus treatment was 117.3 days at 5 mg, and
40.5 days at 10 mg. Sixty-eight of these patients had at
least 1 tumor assessment after receiving a 5-mg dose (53
from the everolimus arm and 15 from the placebo arm).
Representative plots of the measured change in SLD
in individual patients over time as related to dose of
everolimus received are shown in Figure 1. Data for all
407 patients were fit to 2 nested dose-effect models
based on the following equation: dy/dt = r − Edosey,Figure 1 Change in sum of the longest tumor diameters (SLD) over ti
Three treatment groups are shown: 1) patients randomized to placebo wh
randomized to everolimus; and 3) patients randomized to everolimus or pl
5 mg daily. Two different fits of the SLD over time are illustrated for each p
the red dashed line) and ii) a model that assumes E5 6¼ E10 (model 2, shown
indicated by a barplot as a function of time with a value of 10 mg at its m
effect of everolimus 10 mg daily.where y is the SLD, dy/dt is the change in SLD, r is the
placebo growth rate, and Edose is the tumor shrinkage
due to the daily dose, which can change with time. The
nesting arises from the use of two different models for
Edose (model 1: 5 mg and 10 mg everolimus have equal
effects [E5 = E10]; model 2: 5 mg and 10 mg everolimus
have different effects [E5 6¼E10]. It is important to note
that the dose of everolimus could change at any given
time. Some patients who were randomly assigned to pla-
cebo switched to everolimus upon disease progression,
and some patients who received everolimus could have
had their dose reduced to either 5 mg or 0 mg to man-
age an adverse event (AE). This modeling approach was
designed to account for daily changes in everolimus
dose (see the Methods section for a more detailed de-
scription of each model and model parameters). Patients
on either the placebo arm or the everolimus arm who
did not have everolimus dose reduction to 5 mg were
well described by both models. However, a clear distinc-
tion between the 2 models was evident in the subgroup
of patients who had everolimus dose reduction to 5 mg.
Model 2, which allowed the effects of 5 mg and 10 mg
everolimus to differ, provided a significantly better fit
for the data from this patient group than did the modelme in representative patients in relation to everolimus treatment.
o crossed over to everolimus on disease progression; 2) patients
acebo who had at least one everolimus dose reduction from 10 mg to
atient, based on: i) a model that assumes E5 = E10 (model 1, shown in
in the blue solid line). Daily dose of everolimus administered is
aximum. E5, treatment effect of everolimus 5 mg daily; E10, treatment
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The improvement of model 2 over model 1 as applied to
the entire patient population was quantified using a
likelihood ratio test and was found to be highly statisti-
cally significant (P< 0.0001). Of the 407 patients evalu-
ated, only 7 patients presented poor fits to the model; of
these, 4 patients had an SLD that decreased during initial
treatment with everolimus, but began to increase again
after prolonged treatment (Additional file 1: Figure A1).
Parameters for the typical patient in model 2 were,
r = 46.0 ± 5.7 10-3 cm/day, E10 = 3.9 ± 0.5 10
-3/day, and
E5 = 2.3 ± 0.5 10
-3/day. The η-shrinkage on each par-
ameter was ηr = 0.21, ηE10 = 0.36, and ηE5 = 0.80. The
large η shrinkage for E5 may arise because this param-
eter cannot be estimated for many patients who don’t
receive a 5-mg everolimus dose. Model simulation, as
described in the Methods section, was performed to ex-
plore the response of a typical patient maintaining con-
tinuous, uninterrupted dosing. The model predicts a
change in SLD of target lesions after 3 months of
35.6% ± 24.8% on placebo, +7.7% ± 7.0% for a 5-mg dose,
and –7.6% ± 5.5% for a 10-mg dose and after 1 year of
+142.1% ± 98.3% on placebo, +22.4% ± 17.2% for a 5-mg
dose, and –15.7% ± 11.5% for a 10-mg dose (Figure 2).
A covariate analysis was conducted to investigate the im-
pact of prognostic factors of reported relevance in mRCC
on the placebo growth rate (r) and drug effect (E10, E5).
Results of this analysis showed that the only significant pre-
dictor of the model parameters was the tumor size at base-
line. A larger baseline SLD was indicative of increased
placebo growth rate and decreased drug effectiveness with
high statistical significance (P< 0.0001). Other prognostic
factors did not show any significant impact on these para-
meters. We note that the next most predictive covariate
was the corrected calcium levels; however, while this covari-
ate did lead to a numerically better fit, it did not reduce theFigure 2 Simulated changes in tumor size over 1 year in the
average patient treated continuously with either placebo or
everolimus (5 or 10 mg daily).intersubject variability of the model parameters (ηr ηE10)
and thus was not included in the final model.
The final model for the ith patient is given by
dyi=dt ¼ ri  Edoseyi
Edose ¼
( E10;i when dose ¼ 10 mg
E5;i when dose ¼ 5 mg
0 when dose ¼ 0
ri ¼ r  y0;i=y^0
 θ1 þ N 0; ηrð Þ
E10;i ¼ E 10  y0;i=y^0
 θ2 þ N 0; ηE10 
E5;i ¼ E5  y0;i=y^0
 θ2 þ N 0; ηE5 
E ¼ N 0; σEð Þ
where ŷ0 is the median baseline SLD of 14.4 cm, and N
(0,η) indicates a random variable following a normal dis-
tribution with mean 0 and standard deviation to be esti-
mated. The model parameters are summarized in
Table 2. Model qualification showed: 1) good agreement
between the individual, clinically measured values for
SLD and those predicted by the model (Figure 3); 2) ac-
ceptable uncertainty in parameter values, as measured
by the standard error (Table 2); 3) good agreement with
actual patient observations in a simulation of two sets of
10,000 virtual patients (Figure 4). The purpose of the
visual predictive check (VPC) is to ensure that the
model adequately describes the data used to develop it.
We note that at early times, there is good agreement be-
tween the model simulations and the actual data of the
5th, 50th, and 95th percentiles. However, at later times,
the 95th percentile tends to be underestimated. This is
due to informative censoring of the trial; patients with
fast growing tumors are more likely to progress and then
change therapies. For example, a patient on placebo with
a rapidly growing tumor may progress after only two
months and change therapy, whereas a patient with a
slower growing tumor could stay on placebo for
12 months. A more complete simulation of the trial
would ultimately require simulation of the effect of
tumor growth on the therapy received.
As the trial protocol called for dose reductions only
when patients experienced AEs, there is a risk that the
dose–response relationship we have observed for 5 mg
everolimus only applies to patients who experienced
AEs, and not to the entire population. To evaluate this
possibility, individual estimates of E10 were compared
for the subgroups of patients who did have, or who did
not have, any everolimus dose reductions or interrup-
tions. The median drug effect (E10) for these two popula-
tions was found to differ by only 4% (Figure 5). The
minimal difference in E10 observed between patients
who did or did not experience dose reductions or inter-
ruptions suggests that conclusions derived from the
model can be generalized to the overall population.
Table 2 Parameters for final model (Model 2 [E5 6¼ E10]) with all covariates
Variable Units Mean value, θ±SE Intersubject variability, η±SE
Placebo growth rate, r 10-3 cm/day 46.0 ± 5.7 3.5 ± 2.1
Drug effect of 10 mg, E10 10
-3/day 3.9 ± 0.5 0.3 ± 0.2
Drug effect of 5 mg, E5 10
-3/day 2.3 ± 0.5 0.2 ± 0.2
Multiplicative effect of baseline SLD on placebo growth rate, θ1 0.4 ± 0.2 NA
Multiplicative effect of baseline SLD on drug effect, θ2 −0.7 ± 0.2 NA
Residual error, σE cm 1.1 NA
NA, not applicable; SE, standard error; SLD, sum of the longest tumor diameters.
Intersubject variability (η) denotes the standard deviation of the parameter distributions.
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We have developed a pharmacodynamic model to de-
scribe tumor growth in patients with mRCC enrolled in
the phase 3 RECORD-1 trial. Although RECORD-1 did
not have a separate arm in which all patients were admi-
nistered a 5-mg dose of everolimus, the model was able
to detect a difference in the effect of a 5-mg and a 10-
mg dose on reducing the size of target lesions by taking
into account the dosing histories of individual patients
(Figure 1). It is worthy of note that when formulating
the model, the effect of 5 mg everolimus was permitted
to be less than, equal to, or even greater than the effect
10 mg everolimus. For the vast majority of patients, the
model estimated a 10-mg dose of everolimus to be more
effective than a 5-mg dose at shrinking their SLD. Our
model assessed the effect of dose on growth of targetFigure 3 Correlation of the individual predictions of SLD by the
model in which E5 6¼ E10 (model 2) to the actual measured SLD
from each patient. E5, treatment effect of everolimus 5 mg daily;
E10, treatment effect of everolimus 10 mg daily; SLD, sum of the
longest tumor diameters.lesions; thus, it did not capture any potential benefit that
a reduced dose of everolimus may have on nontarget
lesions and/or the prevention of new lesions. Subsequent
efforts to model the dose–response of nontarget and
new lesions demonstrated a marked difference between
placebo and a 10-mg dose of everolimus, but no differ-
ence between 5-mg and 10-mg doses of everolimus was
detected [22]. It may be that there is no difference be-
tween the two everolimus doses on nontarget and new
lesions or that the lack of difference may have been be-
cause the measurements of these lesion types were cat-
egorical rather than continuous; characterization of the
dose–response relationship for these variables requires
additional data.
In a typical statistical analysis of a clinical trial, stand-
ard techniques such as the log-rank test are performed
to compare outcomes in different treatment arms [23].
These techniques have the advantages of simplicity and
a long history of use, but a disadvantage is that informa-
tion about individual patients is ignored. The nonlinear
mixed-effects modeling approach presented here can be
used to describe not only the overall population, but also
the tumor dynamics of each individual patient. This
method offers the possibility to predict clinical observa-
tions as a function of time, and enables evaluation of the
impact of actual dosing history and individual covariates
on the drug effect observed. Modeling a continuous vari-
able (tumor size) has enabled us to quantify a difference in
the effect of 10 mg versus 5 mg everolimus, a difference
that a coarser approach based on modeling categorical vari-
ables, such as RECIST response or PFS, might have missed.
In recent years, an increasing number of reports on
modeling tumor dynamics have appeared in the litera-
ture and a variety of models have been employed that
vary in the following three ways. 1) For placebo-treated
patients, tumor growth has been described as linear, ex-
ponential, logistic, and/or gompertzian [19-21,24]. For
the placebo growth model, we note that therapy is gen-
erally changed once a patient progresses; thus, the long-
term steady state in the gompertz and logistic equations
is rarely observed (Figure 1). 2) Furthermore, the drug
Figure 5 The treatment effects of 10 mg everolimus (E10) for
patients from the everolimus arm (n = 272) who had at least 1
dose reduction to 5 mg and/or 0 mg (n = 174) versus no dose
reduction (n = 98). The line within the grey box indicates the
median value, the grey box indicates the upper and lower quartile,
and the grey lines above and below the box indicate the 5th and
95th percentiles.Figure 4 Visual predictive check (VPC) of 10,000 simulated
patients (A) on placebo before their switch to everolimus, and
(B) on everolimus who received continuous 10 mg dosing
throughout the trial. CI, confidence interval; pctile, percentile; Sim,
simulated; SLD, sum of the longest tumor diameters.
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equation. In our case, we have tried both functional
forms, but since they have similar analytic solutions,
both describe our data reasonably well. 3) Finally, one
can introduce a delay in the time it takes for a drug to
affect the tumor [19]. We found that adding delay be-
tween the dose and the drug effect did not significantly
improve the model fits, and we note that the time-scale
for tumor shrinkage is on the order of months, whereas
the terminal half-life of everolimus when dosed at 10 mg
daily is around 30 h [9], so any delay is likely short com-
pared with the time scales of interest in the study. In fu-
ture work, we plan to formally compare these differentmodels. It should be noted that multiple models would
likely be suitable to describe the data presented herein.
Tumor growth in the majority of RECORD-1 patients
was well described by our model, with exceptions
observed in <2% of patients. Of these patients (n= 7), 4
displayed initial shrinkage followed by growth over the
course of treatment. Because of the small sample size,
further modeling of the tumor dynamics in these par-
ticular patients was not conducted.
Simulations of tumor size in patients after 1 year of con-
tinuous treatment with everolimus show that a significant
antitumor effect is achieved with either a 5-mg or 10-mg
daily dose, but that a substantially improved response
(tumor shrinkage) can be expected in patients receiving the
10-mg daily dose. These results support earlier clinical
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dose based on the complete inhibition of mTOR pathway
signaling observed in tumor tissue from patients receiving
this dosing regimen [8,9,11]. While our results suggest that,
whenever possible, clinical dosing of everolimus should be
maintained at 10 mg daily, the model also demonstrates
that a reduction in tumor burden compared with placebo
can be achieved even in patients who require a dose reduc-
tion to 5 mg daily. This observation is noteworthy, as dose
reductions to 5 mg daily are an integral part of the clinical
strategy recommended by a panel of RECORD-1 investiga-
tors for the management of noninfectious pneumonitis
(grade 2/3), infection (grade 2/3), stomatitis (grade 3), and
metabolic abnormalities (grade 3) that arise as a result of
everolimus therapy [25].
To definitively show that a 10-mg dose of everolimus
is superior to a 5-mg dose, a clinical trial would be
required with 10 mg everolimus and 5 mg everolimus
arms that is powered to measure an outcome difference
(in PFS or overall survival [OS]) between the two doses.
The RECORD-1 trial was not designed to compare these
two different treatment arms (5 mg and 10 mg) to pla-
cebo, and such a 3-arm trial would have required more
patients. Even if such data were available, one would
need to consider that dose in the 10 mg everolimus arm
might have been reduced in some patients due to AEs.
The present analysis allows for the detection of a differ-
ence in the target lesion response to the 2 different
doses in RECORD-1 by modeling the relationship be-
tween the dose given over time and tumor size. Thus,
this work complements the initial biomarker analysis
[11] demonstrating that not only is a 10-mg daily dose
of everolimus more effective than a 5-mg daily dose at
reducing downstream mTOR signaling, but also that a
10-mg daily dose is more effective than a 5-mg daily
dose at shrinking target lesions.Conclusions
In summary, a pharmacodynamic model of tumor re-
sponse has been developed that utilizes the everolimus
dosing history and tumor time course of each patient
from the RECORD-1 trial to directly link everolimus
dose to tumor size. Our analysis demonstrates that a
daily dose of 10 mg is more efficacious than a daily dose
of 5 mg at reducing tumor growth in patients with
mRCC, and supports earlier studies that established
10 mg daily as the preferred clinical dose of everolimus.
These results have direct implications for patients cur-
rently receiving everolimus therapy for whom dose
modification may be an appropriate treatment strategy.
Since tumor size is used directly in the calculation of
PFS, the primary trial end point, this model may provide
improved understanding of the everolimus dose–responserelationship relative to methods that utilize measures of
mTOR pathway inhibition.Methods
Patients
Study design for the double-blind, randomized,
phase 3 RECORD-1 study (Clinicaltrials.gov identi-
fier: NCT00410124) has been described previously
[13,14]. Patients with clear cell mRCC who had
progressed on, or who were intolerant of, treatment with
sunitinib or sorafenib were enrolled. Prior therapy with
cytokines and/or VEGF inhibitors (e.g., bevacizumab)
was permitted. Patients were randomized (2:1) to re-
ceive either everolimus 10 mg daily (n = 277) or placebo
(n = 139) plus best supportive care. Dose reduction to
5 mg everolimus and/or treatment interruption was
allowed for toxicity.
Disease progression was defined according to RECIST
[15]; at least a 20% increase in the SLD of all target
lesions compared with the smallest (nadir) SLD of all
target lesions recorded at or after baseline and/or occur-
rence of a new lesion and/or unequivocal progression of
existing nontarget lesions.
The protocol was approved by the institutional review
boards of the participating institutions and the study
was done in accordance with international standards of
good clinical practice. All patients provided written
informed consent. The study was conducted according
to the ethical principles of the Declaration of Helsinki.Pharmacodynamic data collection and analysis
All RECORD-1 patients with at least one baseline tumor
measurement were included in this retrospective analysis.
The dataset employed included SLD data collected through
the final cut-off date of February 28, 2008. Tumor measure-
ments (performed by CT or MRI scan) were taken at
screening and every 8 weeks for the remainder of the study.
Target lesions were identified at baseline per RECIST cri-
teria; ≤5 measurable lesions per organ and 10 lesions in
total, representative of all involved organs [15]. Target
lesions were selected based on size (longest diameter) and
suitability for accurate repeated measurements (RECIST)
[15]. Most target lesions were metastatic, most frequently
appearing in the lung, liver, and lymph nodes. SLD for all
target lesions was calculated and reported as baseline SLD.
Selection of target lesions and tumor assessments were
conducted both by local investigators and by blinded inde-
pendent central review. However, patients initially rando-
mized to the placebo arm who crossed over to open-label
everolimus following disease progression were subsequently
followed by local investigators only. For this reason, the
local investigator-assessed dataset was employed in our
analysis.
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the First Order Conditional Estimation (FOCE) method
with the $PRED in NONMEM (version VI, GloboMax
LLC). The modeling utilized measurements of SLD at
various time points and was defined for patient i by the
equation dyi/dt= ri – Edose,iyi, in which y= sum of the
longest tumor diameters, dy/dt= rate of change of tumor
size, r=net tumor growth rate for placebo-treated tumors,
Edose= effect of everolimus on tumor growth as a function
of the daily dose. An additive error E was then added to y
(t). The model parameters (ri, E10,i, E5,i) were assumed to
be normally distributed. Using the equation above, 2 dif-
ferent dose-effect models for Edose were explored. The ini-
tial tumor size (y0) was set to the observed baseline tumor
assessment of each patient. Alternatively, we could have
treated y0 as a free parameter that is fit to the data. We
chose this approach instead because we found that the
observed y0 did not follow a true log-normal distribution,
and forcing this distribution via a model led to poor fits
for patients with very large or very small initial SLDs. We
note that this framework allows for daily dose changes to
directly affect the target lesion dynamics.
In model 1, it was assumed that the effect of 5 mg
would be equal to the effect of 10 mg. In model 2, it was
assumed that the effect of 5 mg and 10 mg would be dif-
ferent [E5 6¼E10].
Model1 : Edose;i ¼
(
E10;i when dose > 0
0 when dose ¼ 0
Model2 : Edose;i ¼
E10;i when dose ¼ 10 mg
E5;i when dose ¼ 5 mg
0;when dose ¼ 0
8<
:
The possibility that there was a covariance relationship
between the model parameters was also tested.
In this model, the net growth rate of the tumor (dy/dt)
was defined as the change in tumor size over time,
which may depend upon a number of factors, including
cell proliferation, apoptosis, necrosis, and change in
size of individual tumor cells. The biological mechanisms
underlying change in tumor size cannot be deter-
mined based on SLD alone; thus, the model is ag-
nostic as to the specific mechanisms governing SLD
growth dynamics.
Prognostic factor data collection and analysis
A number of prognostic factors for PFS and OS in the
RECORD-1 trial have been previously reported [14]. We
explored the effect of a subset of these factors on SLD
dynamics, including: hemoglobin, baseline Karnofsky
performance score, corrected serum calcium, number of
other organs involved (including liver, bone, lymph
nodes, and central nervous system), prior therapy (with
either sunitinib or interferon), neutrophil count, andalkaline phosphatase. In addition, baseline SLD was
included as a variable based on results from an explora-
tory analysis. In a process called forward-inclusion [26],
each factor was added in a step-by-step manner to the
base model described above, and the improvement in
model fit was assessed using a likelihood ratio test. If the
factor that led to the largest improvement in fit was
found to have a statistically significant improvement
(P< 0.05), then that factor was added to the model. Using
the resulting new model, the process was repeated until
no additional factors of significance were identified. In
a subsequent process (backward-exclusion [26]), each
factor was then removed step-by-step, and the original
and new models assessed. If the model containing more
factors had an improved fit that was highly significant
(P< 0.001), then the factor was retained in the final
model. In addition, to ensure that the prognostic factor
not only improved the likelihood of the model but also
improved the explanatory power of the model, we also
required the factor to reduce the intersubject variability
of the model parameters (ηr ηE10).
Each prognostic factor or covariate was assumed to
have a multiplicative effect on the parameter of interest,
and continuous and binary covariates were treated
slightly differently. To illustrate how a covariate was
included, we show how the placebo growth rate ri would
vary with baseline SLD (y0, continuous) and prior suniti-
nib therapy (SUN, binary): for the continuous covariate,
we have ri= r× [y0i/y0]
θ+N(0,ηr), where r is the median
placebo growth rate for the population, y0i is the baseline
SLD for patient i, y0 is the median baseline SLD, θ is the
strength of the effect of baseline SLD on the placebo
growth rate, and ηr denotes the intersubject variability of
the population. For binary covariates, we used a similar
functional form with ri= r× θ
SUN +N(0,ηr). Here, SUN=
1 for patients with prior sunitinib therapy and SUN=0
otherwise.
Model qualification and simulation
Model qualification was performed by comparing clinic-
ally measured SLD with those predicted by the model,
evaluating the uncertainty in parameter values, and
using the model to perform a simulation of two sets of
10,000 virtual patients. For the latter, model parameters
were chosen from the parameter distribution obtained in
the final model, and the two sets of virtual patients
simulated were: A) patients on the placebo arm before
cross-over; and B) patients who maintained constant
everolimus dosing throughout the study.
Model simulations of 100,000 patients were performed
to estimate the mean and variability of the predicted re-
sponse of patients who received placebo and for patients
who received everolimus 5 mg and 10 mg continuous
dosing. For each virtual patient, the fixed effects were
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on the uncertainty of the fixed effect estimate; the ran-
dom effects were sampled from a multivariate normal
distribution to account for intersubject variability.
Additional file
Additional 1: Fig. A1. Tumor growth in a small number of RECORD-1
patients was not well described by model 2 with E5 ≠ E10. These
included: i-iv) resistant patients (n = 4); (v) 5 mg of everolimus had an
equivalent effect to 10 mg of everolimus (n = 1); (vi) tumor shrinkage
during placebo treatment, but progression due to nontarget lesions (n =
1); (vii) tumor growth at 10 mg everolimus is faster than tumor growth at
5 mg everolimus (n = 1). E5, treatment effect of everolimus 5 mg daily;
E10, treatment effect of everolimus 10 mg daily; SLD, sum of the longest
tumor diameters.
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